Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cephaeline 对受保护的原代 CLL 细胞具有高度活性(相对 IC50 为 35nM),并通过抑制 HIF-1α± 和扰乱细胞内氧化还原稳态发挥作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 872 | 现货 | ||
5 mg | ¥ 1,830 | 现货 | ||
10 mg | ¥ 2,890 | 现货 | ||
25 mg | ¥ 4,730 | 现货 | ||
50 mg | ¥ 6,590 | 现货 | ||
100 mg | ¥ 8,890 | 现货 |
产品描述 | Cephaeline was highly active against protected primary CLL cells (relative IC50's 35nM ) and acted by repressing HIF-1α± and disturbing intracellular redox homeostasis. |
体外活性 | We compared the transcriptomes of primary CLL cells cocultured or not with protective bone marrow stromal cells (BMSCs) and found that oxidative phosphorylation, mitochondrial function, and hypoxic signaling undergo most significant dysregulation in non-protected CLL cells, with the changes peaking at 6-8 h, directly before induction of apoptosis. A subset of CLL patients displayed a gene expression signature resembling that of cocultured CLL cells and had significantly worse progression-free and overall survival. To identify drugs blocking BMSC-mediated support, we compared the relevant transcriptomic changes to the Connectivity Map database. Correlation was found with the transcriptomic signatures of the cardiac glycoside ouabain and of the ipecac alkaloids emetine and Cephaeline. These compounds were highly active against protected primary CLL cells (relative IC50's 287, 190, and 35 nM, respectively) and acted by repressing HIF-1α± and disturbing intracellular redox homeostasis. We tested emetine in a murine model of CLL and observed decreased CLL cells in peripheral blood, spleen, and bone marrow, recovery of hematological parameters and doubling of median survival (31.5 vs. 15 days, P = 0.0001). |
别名 | 吐根鹼, 吐根酚碱 |
分子量 | 466.61 |
分子式 | C28H38N2O4 |
CAS No. | 483-17-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 33.33 mg/mL (71.43 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol | 1 mM | 2.1431 mL | 10.7156 mL | 21.4312 mL | 53.5779 mL |
5 mM | 0.4286 mL | 2.1431 mL | 4.2862 mL | 10.7156 mL | |
10 mM | 0.2143 mL | 1.0716 mL | 2.1431 mL | 5.3578 mL | |
20 mM | 0.1072 mL | 0.5358 mL | 1.0716 mL | 2.6789 mL | |
50 mM | 0.0429 mL | 0.2143 mL | 0.4286 mL | 1.0716 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cephaeline 483-17-0 Angiogenesis Chromatin/Epigenetic Microbiology/Virology Virus Protease Influenza Virus HIF NSC 32944 inhibit Inhibitor NSC32944 Ebola Filovirus phenolic alkaloid virus NSC-32944 Zika 吐根鹼 吐根酚碱 inhibitor